Iovance Biotherapeutics Inc
IOVA2.060USD
0.0000.00%
Close 10/31, 16:00（ET）Quotes delayed by 15 min
704.35MMarket Cap
LossP/E TTM
More Details of Iovance Biotherapeutics Inc Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Iovance Biotherapeutics Inc Info
Ticker SymbolIOVA
Company nameIovance Biotherapeutics Inc
IPO dateJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Number of employees838
Security typeOrdinary Share
Fiscal year-endJun 20
Address825 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94070
Phone16502607120
Websitehttps://www.iovance.com/
Ticker SymbolIOVA
IPO dateJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Company Executives of Iovance Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
58.60M
97.75%
Rest of world
1.35M
2.25%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Other
68.67%
Shareholders
Shareholders
Proportion
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Other
68.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.59%
Hedge Fund
16.62%
Investment Advisor/Hedge Fund
9.57%
Private Equity
8.01%
Venture Capital
7.77%
Research Firm
5.50%
Individual Investor
0.33%
Bank and Trust
0.25%
Pension Fund
0.20%
Other
30.16%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
649
251.80M
69.59%
-52.91M
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MHR Fund Management LLC
28.97M
8.01%
+4.55M
+18.63%
Jun 30, 2025
Quogue Capital L.L.C.
28.07M
7.76%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
25.03M
6.92%
-2.70M
-9.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.50M
5.39%
-1.03M
-5.02%
Jun 30, 2025
Long Focus Capital Management LLC
11.82M
3.27%
+2.57M
+27.78%
Jun 30, 2025
State Street Investment Management (US)
9.89M
2.73%
-1.15M
-10.42%
Jun 30, 2025
Millennium Management LLC
9.33M
2.58%
+9.17M
+5793.16%
Jun 30, 2025
Invenomic Capital Management LP
8.29M
2.29%
+2.80M
+51.09%
Jun 30, 2025
Two Sigma Investments, LP
7.01M
1.94%
+6.62M
+1666.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.19M
1.71%
+220.76K
+3.70%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.56%
iShares Genomics Immunology and Healthcare ETF
1.33%
WisdomTree BioRevolution Fund
0.64%
Tema Oncology ETF
0.54%
Invesco NASDAQ Future Gen 200 ETF
0.47%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
iShares Biotechnology ETF
0.06%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.56%
iShares Genomics Immunology and Healthcare ETF
Proportion1.33%
WisdomTree BioRevolution Fund
Proportion0.64%
Tema Oncology ETF
Proportion0.54%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
SPDR S&P Biotech ETF
Proportion0.27%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
iShares Biotechnology ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
